Dominic Santoleri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dominic Santoleri has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Paul M. Titchenell
Institute of Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania
4 shared publications - Patrick Seale
University of Pennsylvania
2 shared publications - Alessandra Chesi
Center for Spatial and Functional Genomics, Children’s Hospital of Pennsylvania, Philadelphia, USA
1 shared publication - Andrew D. Wells
Center for Spatial and Functional Genomics, The Children’s Hospital of Philadelphia, Philadelphia, USA
1 shared publication Anna E. Garcia Whitlock
Institute for Diabetes, Obesity, and Metabolism
1 shared publication- Babette S. Zemel
The Perelman School of Medicine at the University of Pennsylvania, Department of Pediatrics , Philadelphia, PA 19104
1 shared publication
Latest Publications
- Open Access
Glucokinase activity suppresses hepatic cholesterol synthesis and triglyceride accumulation: A new model for the effects of the GKRP P466L common human variant
Objective: Glucokinase Regulatory Protein (GKRP) controls the activity of Glucokinase (GCK) to regulate liver glucose uptake and storage. Coding variants in GCKR , the gene encoding GKRP, strongly associate with fatty liver disease, hypertriglyceridemia, and hypercholesterolemia. Here, we sought to investigate the mechanisms by which a common GKRP variant affects hepatic lipid and cholesterol metabolism. Methods: We developed mouse models to examine how the human GKRP P446L variant influences liver and systemic metabolism. Endogenous Gckr expression was ablated in adult mouse hepatocytes, together with re-expression of either human GKRP P446L or the reference GKRP protein. We assessed body weight, adiposity, systemic glucose homeostasis, and hepatic metabolites in mice expressing reference GKRP or GKRP P446L under multiple metabolic conditions. To determine whether the effects of GKRP P446L may result from reduced GCK activity, we analyzed mice with liver-specific deletion of Gck . Results: Hepatic expression of GKRP P446L resulted in reduced GKRP and GCK protein levels and elevated serum cholesterol. Hepatic deletion of Gck in mice recapitulated several effects of GKRP P446L, including increased hepatic cholesterol and triglyceride content. The elevated cholesterol was associated with increased cholesterogenic gene expression and cholesterol synthesis. Hepatic expression of an alternative hexokinase (HKII) normalized the effects of GCK-deficiency, suggesting that impaired glucose phosphorylation underlies the phenotype. Conclusions: The GKRP P446L variant reduced GKRP protein abundance, and diminished GCK activity while increasing cholesterol levels. Loss of GCK elevated cholesterol and hepatic triglyceride levels. Collectively, these findings demonstrate that GCK suppresses hepatic cholesterol synthesis and lipid accumulation, suggesting that reduced GCK activity underlies the metabolic abnormalities associated with the GKRP P446L variant. Highlights: The GKRP P446L variant reduces GKRP protein abundance and diminishes GCK activity. Expression of GKRP P446L in mouse hepatocytes increases serum cholesterol levels. GCK activity suppresses cholesterogenic gene expression and cholesterol synthesis.
Open AccessGlucokinase activity suppresses hepatic cholesterol synthesis and triglyceride accumulation: A new model for the effects of the GKRP P466L common human variant
Objective: Glucokinase Regulatory Protein (GKRP) controls the activity of Glucokinase (GCK) to regulate liver glucose uptake and storage. Coding variants in GCKR , the gene encoding GKRP, strongly associate with fatty liver disease, hypertriglyceridemia, and hypercholesterolemia. Here, we sought to investigate the mechanisms by which a common GKRP variant affects hepatic lipid and cholesterol metabolism. Methods: We developed mouse models to examine how the human GKRP P446L variant influences liver and systemic metabolism. Endogenous Gckr expression was ablated in adult mouse hepatocytes, together with re-expression of either human GKRP P446L or the reference GKRP protein. We assessed body weight, adiposity, systemic glucose homeostasis, and hepatic metabolites in mice expressing reference GKRP or GKRP P446L under multiple metabolic conditions. To determine whether the effects of GKRP P446L may result from reduced GCK activity, we analyzed mice with liver-specific deletion of Gck . Results: Hepatic expression of GKRP P446L resulted in reduced GKRP and GCK protein levels and elevated serum cholesterol. Hepatic deletion of Gck in mice recapitulated several effects of GKRP P446L, including increased hepatic cholesterol and triglyceride content. The elevated cholesterol was associated with increased cholesterogenic gene expression and cholesterol synthesis. Hepatic expression of an alternative hexokinase (HKII) normalized the effects of GCK-deficiency, suggesting that impaired glucose phosphorylation underlies the phenotype. Conclusions: The GKRP P446L variant reduced GKRP protein abundance, and diminished GCK activity while increasing cholesterol levels. Loss of GCK elevated cholesterol and hepatic triglyceride levels. Collectively, these findings demonstrate that GCK suppresses hepatic cholesterol synthesis and lipid accumulation, suggesting that reduced GCK activity underlies the metabolic abnormalities associated with the GKRP P446L variant. Highlights: The GKRP P446L variant reduces GKRP protein abundance and diminishes GCK activity. Expression of GKRP P446L in mouse hepatocytes increases serum cholesterol levels. GCK activity suppresses cholesterogenic gene expression and cholesterol synthesis.
- Open Access
Shared and unique 3D genomic features of substance use disorders across multiple cell types
Recent genome-wide association studies (GWAS) revealed shared genetic components among substance use disorders (SUDs). However, the extent of underlying shared causal variants, effector genes, and cellular contexts, remain unclear. We integrated 3D genomic datasets (high-resolution promoter-focused Capture-C/Hi-C, ATAC-seq, RNA-seq) from 59 diverse human cell types with recent GWAS summary statistics for alcohol (AUD), tobacco (TUD), opioid (OUD), and cannabis use disorder (CanUD). Using stratified LD regression, we determined the proportion of SNP heritability attributable to features in these cell types. We observed significant enrichments ( P <0.05) in 25 cell types. Heritability reached 4.2-fold enrichment for CanUD in iPSC-derived cortical neurons and 6-fold for AUD/TUD in neural progenitors, confirming their relevance for functional exploration. Additionally, pancreatic cell types, notably insulin-secreted beta cells, showed heritability enrichment for TUD (4.8-fold) and CanUD (5.8-fold), suggesting genomic overlap with metabolic processes. Further investigation revealed significant positive genetic correlations between AUD, TUD, and CanUD with type 2 diabetes (T2D) (FDR<0.05). A multi-omic integrated assessment of T2D-SUD correlated loci revealed strong correlations between gene expression and chromatin accessibility at corresponding cis-regulatory elements and shared functional modules. Our study provides new genomic insights into SUDs and implicates specific cell types for targeted functional follow-up to pinpoint causal variant-gene mechanisms.
Open AccessShared and unique 3D genomic features of substance use disorders across multiple cell types
Recent genome-wide association studies (GWAS) revealed shared genetic components among substance use disorders (SUDs). However, the extent of underlying shared causal variants, effector genes, and cellular contexts, remain unclear. We integrated 3D genomic datasets (high-resolution promoter-focused Capture-C/Hi-C, ATAC-seq, RNA-seq) from 59 diverse human cell types with recent GWAS summary statistics for alcohol (AUD), tobacco (TUD), opioid (OUD), and cannabis use disorder (CanUD). Using stratified LD regression, we determined the proportion of SNP heritability attributable to features in these cell types. We observed significant enrichments ( P <0.05) in 25 cell types. Heritability reached 4.2-fold enrichment for CanUD in iPSC-derived cortical neurons and 6-fold for AUD/TUD in neural progenitors, confirming their relevance for functional exploration. Additionally, pancreatic cell types, notably insulin-secreted beta cells, showed heritability enrichment for TUD (4.8-fold) and CanUD (5.8-fold), suggesting genomic overlap with metabolic processes. Further investigation revealed significant positive genetic correlations between AUD, TUD, and CanUD with type 2 diabetes (T2D) (FDR<0.05). A multi-omic integrated assessment of T2D-SUD correlated loci revealed strong correlations between gene expression and chromatin accessibility at corresponding cis-regulatory elements and shared functional modules. Our study provides new genomic insights into SUDs and implicates specific cell types for targeted functional follow-up to pinpoint causal variant-gene mechanisms.
- Open Access
- 30 January 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (7)
mTORC1 controls murine postprandial hepatic glycogen synthesis via Ppp1r3b
In response to a meal, insulin drives hepatic glycogen synthesis to help regulate systemic glucose homeostasis. The mechanistic target of rapamycin complex 1 (mTORC1) is a well-established insulin target and contributes to the postprandial control of liver lipid metabolism, autophagy, and protein synthesis. However, its role in hepatic glucose metabolism is less understood. Here, we used metabolomics, isotope tracing, and mouse genetics to define a role for liver mTORC1 signaling in the control of postprandial glycolytic intermediates and glycogen deposition. We show that mTORC1 is required for glycogen synthase activity and glycogenesis. Mechanistically, hepatic mTORC1 activity promotes the feeding-dependent induction of Ppp1r3b , a gene encoding a phosphatase important for glycogen synthase activity whose polymorphisms are linked to human diabetes. Reexpression of Ppp1r3b in livers lacking mTORC1 signaling enhances glycogen synthase activity and restores postprandial glycogen content. mTORC1-dependent transcriptional control of Ppp1r3b is facilitated by FOXO1, a well characterized transcriptional regulator involved in the hepatic response to nutrient intake. Collectively, we identify a role for mTORC1 signaling in the transcriptional regulation of Ppp1r3b and the subsequent induction of postprandial hepatic glycogen synthesis.
- 30 January 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (7)
Open AccessmTORC1 controls murine postprandial hepatic glycogen synthesis via Ppp1r3b
In response to a meal, insulin drives hepatic glycogen synthesis to help regulate systemic glucose homeostasis. The mechanistic target of rapamycin complex 1 (mTORC1) is a well-established insulin target and contributes to the postprandial control of liver lipid metabolism, autophagy, and protein synthesis. However, its role in hepatic glucose metabolism is less understood. Here, we used metabolomics, isotope tracing, and mouse genetics to define a role for liver mTORC1 signaling in the control of postprandial glycolytic intermediates and glycogen deposition. We show that mTORC1 is required for glycogen synthase activity and glycogenesis. Mechanistically, hepatic mTORC1 activity promotes the feeding-dependent induction of Ppp1r3b , a gene encoding a phosphatase important for glycogen synthase activity whose polymorphisms are linked to human diabetes. Reexpression of Ppp1r3b in livers lacking mTORC1 signaling enhances glycogen synthase activity and restores postprandial glycogen content. mTORC1-dependent transcriptional control of Ppp1r3b is facilitated by FOXO1, a well characterized transcriptional regulator involved in the hepatic response to nutrient intake. Collectively, we identify a role for mTORC1 signaling in the transcriptional regulation of Ppp1r3b and the subsequent induction of postprandial hepatic glycogen synthesis.
- Top Cited PapersOpen Access
- 1 January 2019
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 7 (2) , 447-456
Resolving the Paradox of Hepatic Insulin Resistance
- 1 January 2019
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 7 (2) , 447-456
Top Cited PapersOpen AccessResolving the Paradox of Hepatic Insulin Resistance